<code id='05FCC11BBC'></code><style id='05FCC11BBC'></style>
    • <acronym id='05FCC11BBC'></acronym>
      <center id='05FCC11BBC'><center id='05FCC11BBC'><tfoot id='05FCC11BBC'></tfoot></center><abbr id='05FCC11BBC'><dir id='05FCC11BBC'><tfoot id='05FCC11BBC'></tfoot><noframes id='05FCC11BBC'>

    • <optgroup id='05FCC11BBC'><strike id='05FCC11BBC'><sup id='05FCC11BBC'></sup></strike><code id='05FCC11BBC'></code></optgroup>
        1. <b id='05FCC11BBC'><label id='05FCC11BBC'><select id='05FCC11BBC'><dt id='05FCC11BBC'><span id='05FCC11BBC'></span></dt></select></label></b><u id='05FCC11BBC'></u>
          <i id='05FCC11BBC'><strike id='05FCC11BBC'><tt id='05FCC11BBC'><pre id='05FCC11BBC'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:541
          Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill. -- health policy coverage from STAT
          Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill in 2021. Susan Walsh/AP

          WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT.

          The talks, led by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase. The committee has jurisdiction over Medicare and Medicaid payment policies for hospitals. Other committees that have tried tackling the issue have jurisdiction mostly over the Food and Drug Administration.

          advertisement

          The panel is tentatively aiming to hold a hearing on the issue in November, the sources said. The panel has also started accepting input from outside stakeholders, one lobbyist said.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Researchers tackle phage therapy hurdles for wider adoption
          Researchers tackle phage therapy hurdles for wider adoption

          AttheUniversityofPittsburgh,testingtopickthebestphagetofightinfection-causingbacteria.UniversityofPi

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Annovis Bio delivers candor, but not confidence, on Parkinson’s study

          MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign